Inflation Emergency to Disrupt Your Financial Future?
No doubt, we’re in an inflation emergency. It’s driving up prices more quickly than anything we’ve seen in our lifetime. And it’s barely begun.

What impact will this change have on your money?

How can you prepare starting right now?

Watch the emergency briefing from Expert Sean Brodrick.
>>>

PAA Insider Trading (PharmAust)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$42,500.00
Insider Selling (Last 12 Months): A$0.00

PharmAust Insider Trading History Chart

This chart shows the insider buying and selling history at PharmAust by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PharmAust Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PAA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

PharmAust Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2021Roger AstonInsiderIssued3,649,904A$0.01A$36,499.04
8/24/2021Sam WrightInsiderBuy500,000A$0.09A$42,500.00
8/16/2019Sam WrightInsiderBuy200,000A$0.07A$14,800.00
See Full Table
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

SEC Filings (Institutional Ownership Changes) for PharmAust (ASX:PAA)

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
Read More on PharmAust

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

3,268,637 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of PharmAust?

PharmAust's top insider shareholders include:
  1. Roger Aston (Insider)
  2. Sam Wright (Insider)
Learn More about top insider investors at PharmAust.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.